Gene Biotherapeutics Inc. (CRXM)
Stock Price: $0.0511 USD
0.0011 (2.20%)
Updated Jul 27, 2021 1:51 PM EDT - Market closed
| Market Cap | 2.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 866,675 |
| Shares Out | 14.49M |
| EPS (ttm) | 0.06 |
| PE Ratio | 0.85 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 27 |
| Last Price | $0.0511 |
| Previous Close | $0.0500 |
| Change ($) | 0.0011 |
| Change (%) | 2.20% |
| Day's Open | 0.0478 |
| Day's Range | 0.0460 - 0.0551 |
| Day's Volume | 496,466 |
| 52-Week Range | 0.0245 - 0.1079 |
News
There are no news available yet.
About CRXM
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebr... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Christopher Reinhard | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol CRXM |